Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells
- PMID: 14679009
Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells
Abstract
Rapamycin and its analogues have shown promising anticancer activities in preclinical and clinical studies. However, the mechanism whereby rapamycin inhibits signaling through the mammalian target of rapamycin (mTOR) remains poorly understood. Here, we show that the FKBP12/rapamycin complex is an essentially irreversible inhibitor of mTOR kinase activity in vitro. However, we observe no suppression of mTOR catalytic activity after immunoprecipitation from rapamycin-treated cells. These results suggest either that rapamycin acts as a reversible kinase inhibitor in intact cells or that the cellular effects of rapamycin are not mediated through global suppression in mTOR kinase activity. To better understand the cellular pharmacology of rapamycin, we compared the individual and combined effects of rapamycin and kinase-inactive mTOR expression on a panel of mTOR-dependent cellular responses. These studies identified glycolytic activity, amino acid transporter trafficking, and Akt kinase activity as novel, mTOR-modulated functions in mammalian cells. Whereas kinase-inactive mTOR did not enhance the decreases in cell size and glycolysis induced by rapamycin, expression of this mTOR mutant significantly enhanced the inhibitory effects of rapamycin on cell proliferation, 4EBP1 phosphorylation, and Akt activity. Unexpectedly, amino acid transporter trafficking was perturbed by kinase-inactive mTOR but not by rapamycin, indicating that this process is rapamycin insensitive. These results indicate that rapamycin exerts variable inhibitory actions on mTOR signaling functions and suggest that direct inhibitors of the mTOR kinase domain will display substantially broader anticancer activities than rapamycin.
Similar articles
-
Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.Mol Cancer Res. 2005 Nov;3(11):635-44. doi: 10.1158/1541-7786.MCR-05-0063. Mol Cancer Res. 2005. PMID: 16317089
-
Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.IUBMB Life. 2007 Nov;59(11):717-21. doi: 10.1080/15216540701646484. IUBMB Life. 2007. PMID: 17968710
-
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.Cancer Res. 2005 Nov 1;65(21):9953-61. doi: 10.1158/0008-5472.CAN-05-0921. Cancer Res. 2005. PMID: 16267020
-
An expanding role for mTOR in cancer.Trends Mol Med. 2005 Aug;11(8):353-61. doi: 10.1016/j.molmed.2005.06.007. Trends Mol Med. 2005. PMID: 16002336 Review.
-
Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.J BUON. 2006 Jul-Sep;11(3):267-76. J BUON. 2006. PMID: 17309148 Review.
Cited by
-
Regulation of leucine uptake by tor1+ in Schizosaccharomyces pombe is sensitive to rapamycin.Genetics. 2005 Feb;169(2):539-50. doi: 10.1534/genetics.104.034983. Epub 2004 Sep 30. Genetics. 2005. PMID: 15466417 Free PMC article.
-
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.J Neurosci. 2010 Jan 20;30(3):1166-75. doi: 10.1523/JNEUROSCI.3944-09.2010. J Neurosci. 2010. PMID: 20089925 Free PMC article.
-
FGFR1 forms an FRS2-dependent complex with mTOR to regulate smooth muscle marker gene expression.Biochem Biophys Res Commun. 2009 May 1;382(2):424-9. doi: 10.1016/j.bbrc.2009.03.040. Epub 2009 Mar 13. Biochem Biophys Res Commun. 2009. PMID: 19285959 Free PMC article.
-
The PI 3-kinase and mTOR signaling pathways are important modulators of epithelial tubule formation.J Cell Physiol. 2008 Aug;216(2):469-79. doi: 10.1002/jcp.21419. J Cell Physiol. 2008. PMID: 18366086 Free PMC article.
-
DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase.Oncotarget. 2016 Apr 26;7(17):24154-71. doi: 10.18632/oncotarget.8131. Oncotarget. 2016. PMID: 26992219 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous